Fifteen percent of lung cancer cases occur in never-smokers and show characteristics that are molecularly and clinically distinct from those in smokers. Epidermal growth factor receptor (EGFR) gene mutations, which are correlated with sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs), are more frequent in never-smoker lung cancers. In this study, microRNA (miRNA) expression profiling of 28 cases of never-smoker lung cancer identified aberrantly expressed miRNAs, which were much fewer than in lung cancers of smokers and included miRNAs previously identified (e.g., up-regulated miR-21) and unidentified (e.g., down-regulated miR-138) in those smoker cases. The changes in expression of some of these miRNAs, including miR-21, were more remarkable in cases with EGFR mutations than in those without these mutations. A significant correlation between phosphorylated-EGFR (p-EGFR) and miR-21 levels in lung carcinoma cell lines and the suppression of miR-21 by an EGFR-TKI, AG1478, suggest that the EGFR signaling is a pathway positively regulating miR-21 expression. In the never-smoker-derived lung adenocarcinoma cell line, H3255, with mutant EGFR and high levels of p-EGFR and miR-21, antisense inhibition of miR-21 enhanced AF1478-induced apoptosis. In a never-smoker-derived adenocarcinoma cell line, H441, with wild-type EGFR, the antisense miR-21 not only showed the additive effect with AG1478 but also induced apoptosis by itself. These results suggest that aberrantly increased expression of miR-21, which is enhanced further by the activiated EGFR signaling pathway, plays a significant role in lung carcinogenesis in never-smokers as well as in smokers, and is a potential therapeutic target in both EGFR-mutant and wild-type cases.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010874-02
Application #
7965776
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2009
Total Cost
$733,746
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Kohno, Takashi; Ichikawa, Hitoshi; Totoki, Yasushi et al. (2012) KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18:375-7
Taga, Masataka; Mechanic, Leah E; Hagiwara, Nobutoshi et al. (2012) EGFR somatic mutations in lung tumors: radon exposure and passive smoking in former- and never-smoking U.S. women. Cancer Epidemiol Biomarkers Prev 21:988-92
Heegaard, Niels H H; Schetter, Aaron J; Welsh, Judith A et al. (2012) Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 130:1378-86
Coté, Michele L; Liu, Mei; Bonassi, Stefano et al. (2012) Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer 48:1957-68
Gill, R K; Yang, S-H; Meerzaman, D et al. (2011) Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene 30:3784-91
Saito, Motonobu; Schetter, Aaron J; Mollerup, Steen et al. (2011) The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 17:1875-82
Schetter, Aaron J; Harris, Curtis C (2011) MicroRNAs as molecular classifiers for cancer. Cell Cycle 10:2827-8
Au, Amy Y M; Hackl, Torben; Yeager, Thomas R et al. (2011) Telomerase activity in pleural malignant mesotheliomas. Lung Cancer 73:283-8
Volinia, Stefano; Galasso, Marco; Costinean, Stefan et al. (2010) Reprogramming of miRNA networks in cancer and leukemia. Genome Res 20:589-99
Tahara, Eiichi; Yasui, Wataru; Ito, Hisao et al. (2010) Recent progress in carcinogenesis, progression and therapy of lung cancer: the 19th Hiroshima Cancer Seminar: the 3rd Three Universities' Consortium International Symposium, November 2009. Jpn J Clin Oncol 40:702-8

Showing the most recent 10 out of 16 publications